However, our findings differed from those of a study on human epidermal growth factor receptor 2 (HER2)-mutated lung cancer, which reported a median OS of 89.6 months and a 5-year survival probability of 70% for stage I–III disease.23 A meta-analysis of over 6000 patients showed that HER2 protein overexpression is a poor prognostic factor in early-stage NSCLC (HR 1.48 (1.2–0.80), p < 0.0001), but only a non-significant trend was seen for HER2 amplification assessed by FISH (HR 1.14 (0.72–1.83)).24 This meta-analysis did not report on HER2 mutation status. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.